专家序言

《心肺移植特刊》序言

Published at: 2016年第1卷第68期

Don Hayes Jr 1 , Bryan A. Whitson 2
1 Associate Professor of Pediatrics and Internal Medicine. Medical Director, Advanced Lung Disease Program. Medical Director, Lung and Heart-Lung Transplantation Programs, Nationwide Children’s Hospital, The Ohio State University, Columbus, Ohio 43205, USA
2 Assistant Professor of Surgery. Surgical Director of the End-Stage Cardiopulmonary Failure Program. Co-Director COPPER Laboratory, Division of Cardiac Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
关键词:

序言

心肺疾病分别是全世界主要的发病及死亡原因。由于生理需要,任何脏器的疾病都可导致其他脏器功能衰竭。器官移植是终末期心、肺或者心肺功能衰竭唯一能被接受的治疗措施。

近来,心肺支持技术的进步使得机械装置迅速成为常规治疗的一部分,比如心室辅助装置和体外生命器官支持装置。这些装置的科学和相关技术正在开展。合适病例群体的筛选和器官供体的充足依旧是理想的长期临床疗效的重要限制性因素。

《胸部疾病杂志》期刊提供了当今多数心、肺及心肺衰竭和心胸移植外科问题的深度分析。这些问题涉及成人及儿童群体,包括了疾病指征、筛选标准、外科技巧、免疫抑制以及心肺机械装置支持。

该期刊面纠集全世界的力量来治疗心肺疾病,但首选且更理想的是心肺疾病的预防及其治疗;然而,标准治疗对部分终末期心肺疾病患者无效,因此治疗措施必须不断的更新。一组深受尊敬的作者已创立一本期刊,来讨论心肺功能衰竭目前最佳的治疗,同时也提供了进一步治疗的机会。

Don Hayes Jr, MD, MS, MEd1, Bryan A. Whitson, MD, PhD2

1Associate Professor of Pediatrics and Internal Medicine. Medical Director, Advanced Lung Disease Program. Medical Director, Lung
and Heart-Lung Transplantation Programs, Nationwide Children’s Hospital, The Ohio State University, Columbus, Ohio 43205, USA
(Email: hayes.705@osu.edu.)

2Assistant Professor of Surgery. Surgical Director of the End-Stage Cardiopulmonary Failure Program. Co-Director COPPER
Laboratory, Division of Cardiac Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
(Email: bryan.whitson@osumc.edu.)

doi: 10.3978/j.issn.2072-1439.2014.07.36
Disclosure: The authors declare no conflict of interest.
View this article at: http://dx.doi.org/10.3978/j.issn.2072-1439.2014.07.36

Cite this article as: Hayes D Jr, Whitson BA. Preface. J Thorac Dis 2014;6(8):1017. doi: 10.3978/j.issn.2072-1439.2014.07.36

 

编译

张婉,复旦大学附属华东医院血管外科,主治医师,研究方向为血管组织工程。至今已在中华系列杂志发表多篇论文,多次参与原版英文书籍及文献翻译工作。

comments powered by Disqus

附件